← Leaderboards
Omayma O Alshaarawy
Michigan State University
$2,617,761
Attributed
$2,617,761
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $576K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,617,761 · 3
By mechanism
R01$1,692,524 · 1
R00$744,055 · 1
K99$181,182 · 1
Top collaborators
No co-investigators on record.
Most similar at Michigan State University
Same institution · by research overlap
- Honglei Chen$8,079,575
Others in their field
Top investigators on “Cannabinoids”
- Alexandros Makriyannis · University Of Connecticut Storrs$39,379,878
- Yasmin L Hurd · Icahn School Of Medicine At Mount Sinai$31,535,958
- Deepak Cyril D'souza · Va Connecticut Healthcare System$18,310,025
- Daniele Piomelli · University Of California Irvine$17,726,721
- Kenneth P. Mackie · Queen'S Medical Center$16,568,516
- Jenny L. Wiley · Virginia Commonwealth University$14,895,613
Research focus
CannabinoidsBlood PressureChronicAdultMeasurementImmune ResponseCohortInflammationMarijuana SmokingReportingCannabisProspective StudiesLaboratoriesInflammatoryEpidemiology StudyRecruitAttentionAnimal ModelCareer DevelopmentCardiometabolic RiskCareerCatchment AreaBiracialBiological Markers
Grant awards (8)
Cannabis use and cardiovascular health outcomes among patients with high blood pressure$576,008
R01 · FY2025 · DA · contact PI
Cannabis use and cardiovascular health outcomes among patients with high blood pressure$574,233
R01 · FY2024 · DA · contact PI
Cannabis use and cardiovascular health outcomes among patients with high blood pressure$542,283
R01 · FY2023 · DA · contact PI
Using pre-clinical biomarkers and epidemiological models to assess the effects of cannabinoids on disease$247,016
R00 · FY2020 · AT · contact PI
Using pre-clinical biomarkers and epidemiological models to assess the effects of cannabinoids on disease$248,039
R00 · FY2019 · AT · contact PI
Using pre-clinical biomarkers and epidemiological models to assess the effects of cannabinoids on disease$249,000
R00 · FY2018 · AT · contact PI
Using pre-clinical biomarkers and epidemiological models to assess the effects of cannabinoids on disease$90,591
K99 · FY2017 · AT · contact PI
Using pre-clinical biomarkers and epidemiological models to assess the effects of cannabinoids on disease$90,591
K99 · FY2016 · AT · contact PI